UMSC01 not checked
Ever Supreme Bio Technology Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.”In the company’s words, NCT06147986 on ClinicalTrials.gov
- Main trialPhase 2
- “This phase IIa study is to identify the efficacy and safety of IC(intracoronary) and IV(Intravenous) administrations of UMSC01 in patients with STEMI . This product is a new cell therapy product for treating AMI and produced by Ever Supreme Bio Technology Co., Ltd in Taiwan. The previous Phase I, open-label, single arm, single center study was conducted to evaluate the safety and to explore the efficacy of UMSC01 in subjects with STEMI via intracoronary administration followed by intravenous infusion. This first-in-human Phase I study of UMSC01 was completed on August 2nd, 2021. Among 8…”In the company’s words, NCT06147986 on ClinicalTrials.gov
Other drugs for ST Elevation Myocardial Infarction
- InclisiranNovartis · Phase 3
- ZalunfibanCeleCor Therapeutics · Phase 3
- SGC001Beijing Sungen Biomedical Technology Co., Ltd · Phase 2
- XolatrypNyrada Pty Ltd · Phase 2
- NL005Beijing Northland Biotech. Co., Ltd. · Phase 2
- EvolocumabAmgen · Marketed (Phase 4 trial)
Coming up3
- 24 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Oct 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 24 Jun 2027 | Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients | |
| Phase 1/2Active, not recruiting | 31 Dec 2027 | Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19 | |
| Phase 1/2Recruiting | 31 Oct 2028 | Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis | |
| Phase 1Completed | 2 Aug 2021 | Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction | |
| Phase 1Completed | 23 Jan 2026 | Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026